ANLI(SZ:300218) Sou Hu Cai Jing·2025-09-15 15:08Core Viewpoint - Amway Co., Ltd. (300218) is actively engaging with investors and addressing concerns regarding its production capacity, product applications, and stock performance, while also reporting mixed financial results for the first half of 2025 [1][2][3]. Financial Performance - For the first half of 2025, the company reported a main revenue of 1.099 billion yuan, a year-on-year decrease of 2.4% [2]. - The net profit attributable to shareholders was 93.25 million yuan, reflecting a year-on-year increase of 0.91% [2]. - The net profit excluding non-recurring items was 88.57 million yuan, showing a year-on-year increase of 5.53% [2]. - In Q2 2025, the company recorded a single-quarter main revenue of 544 million yuan, down 7.01% year-on-year [3]. - The single-quarter net profit attributable to shareholders was 46.83 million yuan, a decrease of 8.41% year-on-year [3]. - The single-quarter net profit excluding non-recurring items was 44.14 million yuan, down 4.26% year-on-year [3]. - The company's debt ratio stood at 28.55%, with investment income reported at -1.19 million yuan and financial expenses at 1.35 million yuan [3]. - The gross profit margin was 26.07% [3]. Stock and Market Engagement - As of September 10, 2025, the total number of shareholders was 14,869 [1]. - The company has not seen any share reductions from its controlling shareholders since its listing, and it completed a share buyback plan in June 2025, acquiring 1.5987 million shares [1]. - The stock has experienced fluctuations, attributed to various market factors, and the management is focused on enhancing corporate value and aligning market value with intrinsic value [1]. Product Development and Partnerships - The company is exploring new business growth areas, particularly in emerging fields such as humanoid robot skin, and is in discussions with leading industry players [1]. - Current collaborations have not yet resulted in substantial business transactions, but the company is committed to advancing product development based on customer needs [1]. Analyst Ratings - In the last 90 days, five institutions have provided ratings for the stock, with four recommending a buy and one recommending an increase [3].